QIAGEN’s careHPV™ Test Wins WHO Prequalification Status for Cervical Cancer Screening
WHO Prequalification recognizes the important role that the careHPV Test can have in screening women in
emerging countries for HPV
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its careHPV™ Test, one of the only
molecular diagnostics for high-risk human papillomavirus (HPV) designed to screen women in low-resource settings, has been added to
the World Health Organization (WHO) list of prequalified in vitro diagnostics (IVDs). HPV is the primary cause of cervical cancer,
so screening women for the presence of the virus is a critical aspect for prevention and early treatment of the deadly cancer.
The careHPV Test was launched globally in 2010 and through numerous pilot studies has demonstrated to be a more
sensitive alternative to cytology and visual inspection based methods for the detection of pre-cancerous cell abnormalities. The
WHO’s evidence-based listing is expected to expand the availability of this critical diagnostic tool in countries that rely on the
global organization’s list in making purchasing decisions. The WHO Prequalification status will significantly broaden access to HPV
DNA testing to areas of the world with a high burden of cervical cancer.
“The WHO prequalified IVD listing is a ‘stamp of approval’ for our innovative careHPV Test, and this will encourage
authorities to adopt efficient, highly accurate HPV screening for prevention of cervical cancer in settings with limited healthcare
infrastructure,” said Thierry Bernard, Senior Vice President, Molecular Diagnostics Business Area, for QIAGEN. “China routinely
uses careHPV in rural or low-resource areas, and QIAGEN partners with non-governmental organizations and health ministries
in developing countries. We expect the WHO listing to drive further dissemination of this important tool for women’s health.”
Please find the full press release here
Investor Relations
John Gilardi
+49 2103 29 11711
or
Dr. Sarah Fakih
+49 2103 29 11457
e-mail: ir@QIAGEN.com
or
Public Relations
Dr. Thomas Theuringer
+49 2103 29 11826
or
Robert Reitze
+49 2103 29 11676
e-mail: pr@QIAGEN.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180801005085/en/